IQVIA Holdings Inc. (NYSE:IQV) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of IQVIA Holdings Inc. (NYSE:IQV) have earned an average rating of “Moderate Buy” from the twenty-one research firms that are currently covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation, seventeen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $251.22.

IQV has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft dropped their target price on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research report on Friday, November 1st. William Blair restated an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. JPMorgan Chase & Co. reduced their target price on IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a report on Tuesday, February 18th. StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. Finally, The Goldman Sachs Group reduced their price target on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st.

IQVIA Stock Up 1.9 %

Shares of NYSE:IQV opened at $194.71 on Thursday. IQVIA has a 1 year low of $187.62 and a 1 year high of $261.73. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The stock’s 50-day moving average is $199.52 and its 200 day moving average is $215.96. The company has a market cap of $34.29 billion, a PE ratio of 25.96, a P/E/G ratio of 1.99 and a beta of 1.48.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Sell-side analysts anticipate that IQVIA will post 10.84 EPS for the current year.

Insider Buying and Selling

In other IQVIA news, Director John G. Danhakl bought 1,275 shares of IQVIA stock in a transaction on Tuesday, December 3rd. The stock was acquired at an average price of $200.58 per share, with a total value of $255,739.50. Following the acquisition, the director now owns 1,275 shares in the company, valued at approximately $255,739.50. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On IQVIA

Several institutional investors have recently modified their holdings of IQV. Creative Planning lifted its stake in IQVIA by 17.8% during the 3rd quarter. Creative Planning now owns 21,013 shares of the medical research company’s stock valued at $4,980,000 after acquiring an additional 3,176 shares during the period. Blue Trust Inc. raised its holdings in shares of IQVIA by 266.5% during the third quarter. Blue Trust Inc. now owns 1,030 shares of the medical research company’s stock valued at $244,000 after purchasing an additional 749 shares during the last quarter. Raleigh Capital Management Inc. lifted its position in IQVIA by 27.9% during the third quarter. Raleigh Capital Management Inc. now owns 1,688 shares of the medical research company’s stock valued at $400,000 after purchasing an additional 368 shares during the period. Foundations Investment Advisors LLC grew its position in IQVIA by 2.4% in the 3rd quarter. Foundations Investment Advisors LLC now owns 5,934 shares of the medical research company’s stock worth $1,406,000 after purchasing an additional 141 shares during the period. Finally, Signaturefd LLC raised its stake in IQVIA by 5.0% during the 3rd quarter. Signaturefd LLC now owns 2,548 shares of the medical research company’s stock valued at $604,000 after buying an additional 121 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.